223 related articles for article (PubMed ID: 30526126)
1. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
Engeroff P; Bachmann MF
Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
Mohsen MO; Heath MD; Cabral-Miranda G; Lipp C; Zeltins A; Sande M; Stein JV; Riether C; Roesti E; Zha L; Engeroff P; El-Turabi A; Kundig TM; Vogel M; Skinner MA; Speiser DE; Knuth A; Kramer MF; Bachmann MF
J Immunother Cancer; 2019 Apr; 7(1):114. PubMed ID: 31027511
[TBL] [Abstract][Full Text] [Related]
3. Virus-like particle vaccines: immunology and formulation for clinical translation.
Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
[TBL] [Abstract][Full Text] [Related]
4. Meeting report VLPNPV: Session 3: Immune responses.
Morrison TG
Hum Vaccin Immunother; 2014; 10(10):3064-7. PubMed ID: 25529229
[TBL] [Abstract][Full Text] [Related]
5. Engineering virus-like particles as vaccine platforms.
Frietze KM; Peabody DS; Chackerian B
Curr Opin Virol; 2016 Jun; 18():44-9. PubMed ID: 27039982
[TBL] [Abstract][Full Text] [Related]
6. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant formulations for virus-like particle (VLP) based vaccines.
Cimica V; Galarza JM
Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
[TBL] [Abstract][Full Text] [Related]
8. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
[TBL] [Abstract][Full Text] [Related]
9. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
10. [Virus-Like Particles as an Instrument of Vaccine Production].
Syomin BV; Ilyin YV
Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
[TBL] [Abstract][Full Text] [Related]
11. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
13. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
Garg H; Sedano M; Plata G; Punke EB; Joshi A
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
[TBL] [Abstract][Full Text] [Related]
14. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines.
Caldeira JC; Perrine M; Pericle F; Cavallo F
Viruses; 2020 Apr; 12(5):. PubMed ID: 32349216
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
16. Meeting report VLPNPV: Sessions 1 and 2: Plenary.
Sainsbury F
Hum Vaccin Immunother; 2014; 10(10):3060-3. PubMed ID: 25485812
[TBL] [Abstract][Full Text] [Related]
17. Meeting report VLPNPV: Session 5: Plant based technology.
Meador LR; Mor TS
Hum Vaccin Immunother; 2014; 10(10):3068-73. PubMed ID: 25581535
[TBL] [Abstract][Full Text] [Related]
18. Meeting report VLPNPV: Session 10: Virus-like particle and nano-particle vaccines.
Effio CL; Hubbuch J
Hum Vaccin Immunother; 2014; 10(10):3080-2. PubMed ID: 25458914
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
Cárdenas-Vargas A; Elizondo-Quiroga D; Gutierrez-Ortega A; Charles-Niño C; Pedroza-Roldán C
Viral Immunol; 2016 Dec; 29(10):557-564. PubMed ID: 27834623
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
